DOW JONES22,154.33+517.55 2.39%
S&P 5002,609.30+67.83 2.67%
NASDAQ7,707.61+205.23 2.74%

Morgan Stanley Downgrades Rubius Therapeutics to Equal-Weight, Lowers Price Target to $4

Morgan Stanley analyst Matt Harrison downgrades Rubius Therapeutics (NASDAQ:RUBY) from Overweight to Equal-Weight and lowers the price target from $15 to $4.

Benzinga · 03/13/2020 15:10

Morgan Stanley analyst Matt Harrison downgrades Rubius Therapeutics (NASDAQ:RUBY) from Overweight to Equal-Weight and lowers the price target from $15 to $4.